landmarknew treatment
Canakinumab FDA/EMA-approved for TRAPS based on CLUSTER trial
TNF Receptor-Associated Periodic Syndrome →Summary
Canakinumab received FDA and EMA approval for TRAPS in 2016-2017 based on the pivotal CLUSTER trial, which demonstrated that canakinumab 150 mg every 4 weeks achieved complete disease control in 45% of TRAPS patients at 16 weeks versus 8% with placebo. This was the first approved targeted therapy for TRAPS.
Related treatments
More from TNF Receptor-Associated Periodic Syndrome
significantTreatment update
Long-term CLUSTER extension confirms sustained canakinumab efficacy in TRAPS
incrementalTreatment update
Tocilizumab case reports expand treatment options for refractory TRAPS
significantNew research
French national series quantifies AA amyloidosis severity in TRAPS
significantGenetic finding
INSAID classification system validated for TRAPS treatment decisions
ID: traps-update-5Type: new_treatmentImpact: landmark